A review on an update of NS5B polymerase hepatitis C virus inhibitors

European Review for Medical and Pharmacological Sciences

Volumn 16, Issue 5, 2012, Pages 667-671

  Varshney, Jonish ^a   Sharma, Pk ^a   Sharma, A ^a  

^a MEERUT INSTITUTE OF ENGINEERING AND TECHNOLOGY   (India)

Author keywords

Hepatitis; Interferon; NS3; NS5B

Indexed keywords

GLYCOPROTEIN E1; GLYCOPROTEIN E2; GSK 625433; MERICITABINE; MK 0608; MONOCLONAL ANTIBODY; NESBUVIR; NONSTRUCTURAL PROTEIN 2; NONSTRUCTURAL PROTEIN 3; NONSTRUCTURAL PROTEIN 4A; NONSTRUCTURAL PROTEIN 4B; NONSTRUCTURAL PROTEIN 5A; NONSTRUCTURAL PROTEIN 5B; NUCLEOSIDE DERIVATIVE; RNA DIRECTED RNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VCH 759; VCH 916; VIRUS RNA; ANTIVIRUS AGENT; ENZYME INHIBITOR; NS 5 PROTEIN, HEPATITIS C VIRUS; NS-5 PROTEIN, HEPATITIS C VIRUS; VIRUS PROTEIN;

ANTIBODY RESPONSE; BLOOD TRANSFUSION; BRANCHED DNA SIGNAL AMPLIFICATION ASSAY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ENZYME STRUCTURE; ENZYME SUBUNIT; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOBLOTTING; NONHUMAN; OPEN READING FRAME; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN FUNCTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; REVIEW; RNA SYNTHESIS; SEROCONVERSION; SEROLOGY; UNTRANSLATED REGION; VIRUS GENOME; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS TRANSMISSION; ANIMAL; ANTIVIRAL RESISTANCE; BLOOD; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG EFFECT; ENZYMOLOGY; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; STRUCTURE ACTIVITY RELATION; TREATMENT OUTCOME; VIRUS LOAD;

ANIMALS; ANTIVIRAL AGENTS; DRUG DESIGN; DRUG RESISTANCE, VIRAL; ENZYME INHIBITORS; HEPACIVIRUS; HEPATITIS C; HUMANS; MOLECULAR STRUCTURE; RNA, VIRAL; STRUCTURE-ACTIVITY RELATIONSHIP; TREATMENT OUTCOME; VIRAL LOAD; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84864089619     PISSN: 11283602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. ADACHI T, AGO H, HABUKA N. Recent advances in the development on NS5B polymerase inhibitors for the treatment of hepatitis C virus infection. Biochem Biophys Acta 2002; 39: 1601.
2. SHEPARD CW, ALTER MJ. Structure and functions of hepatitis C virus proteins. Lancet 2005; 5: 524.
3. EL-SERAG HB. Hepatocellular carcinoma: Recent trends in United States. Gastroenterology 2004; 5: S27-S34.
4. DI BISCEGLIE AM, MC HUTCHISON JC. Rice, the way forwarding HCV treatment-finding the right. Hepatology 2002; 35: 224-231.
5. TAN SL, PAUSE A, SHI Y. Hep C therapeutics: Current status and emerging strategies. Nat Rev Drug Disc 2002; 1: 867-881.
6. BEAULIEU P-L. Recent advances in the development on NS5B polymerase. Expert Opin Ther Pat 2009; 19: 145.
7. MANNS MP, FOSTER GR, ROCKSTROH JK, ZEUZEM S, ZOULIM F, HOUGHTON M. The way forwarding HCV treatment-finding the right. Nat Rev Drug Disc 2007; 6: 991-1000.
8. TAN SL, PAUSE A, SHI Y, SONENBERG N. Hepatitis C therapeutics: Current status and emerging strategies. Nat Rev Drug Disc 2002; 1: 867-881.
9. KATO N, HIJIKATA M, OOTSUYAMA Y, NAKAGWA, M, OHKOSHI S, SUGIMURA T, SHIMOTOHNO K. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acad Sci U S A 1990; 87: 9524-9528.
10. CHOO QL, RICHMAN KH, HAN JH, BERGER K, LEE C, DONG C, GALLEGOS C, COIT D, MEDINA-SELBY A, BARR PJ, WEINER AJ, BRADLEY DW, KUO G, HOUGHTON M. Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A 1991; 88: 2451-2455.
11. TAKAMIZAWA A, MORI C, FUKE I, MANABE S, MURAKAMI S, FUJITA J, ONISHI E, ANDOH T, YOSHIDA I, OKAYAMA H. Structure and organization of the hepatitis C virus genome isolated from human carriers. J Virol 1991; 65: 1105-1113.
12. DELEERSNYDER V, PILLEZ A, WYCHOWSKI C, BLIGHT K, XU J, HAHN YS, RICE CM, DUBUISSON J. Formation of native hepatitis C virus glycoprotein complexes. J Virol 1997; 71: 697-704.
13. DIVINEY S, TUPLIN A, STRUTHERS M. A hepatitis C virus cis-acting replication element forms a longrange RNA-RNA interaction with upstream RNA sequences in NS5B. J Virol 2008; 18: 9008-9022.
14. SHI ST, LEE KJ, AIZAKI H, HWANG SB, LAI MM. Hepatitis C virus RNA replication occurs on a detergentresistant membrane that co fractionates with caveolin-2. J Virol 2003; 7: 4160-4168.
15. MORADPOUR D, PENIN F, RICE CM. Replication of hepatitis C virus. Nat Rev Microbiol 2007; 5: 453-463.
16. MCLAUCHLAN J. Hepatitis C virus: Viral proteins on the move. Biochem Soc Trans 2009; 37: 986-990.
17. GALE M, FOY EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005; 5: 939-945.
18. KREKULOVA L, REHAK V, RILEY L-W. Structure and functions of hepatitis C virus proteins: 15 years after. Folia Microbiol (Praha) 2006; 51: 665-680.
19. MCGIVERN DR, LEMON SM. Tumor suppressors, chromosomal instability and hepatitis C virus-associated liver cancer. Annu Rev Pathol 2009; 4: 399-415.
20. TOMEI L. NS3 is a serine protease required for processing of hepatitis C virus polyprotein. J Virol 1993; 67: 4017-4026.
21. NAKASHIMA K, IKEMATSU H, HAYASHI J, KISHIHARA Y. Intrafamilial transmission of hepatitis C virus among the population of an endemic area of Japan. JAMA 1995; 274: 1459-1460.
22. FARHANA M, HUSSAIN I, HAROON T-S. Hepatitis C: The dermatologic profile. J Pak Assoc Derm 2009; 18: 171-181.
23. TANAKA E, OHUE C, AOYAGI K, YAMAGUCHI K, YAGI S, KIYOSAWA K. Evaluation of a new enzyme immunoassay for hepatitis C virus (HCV) core antigen with clinical sensitivity approximating that of genomic amplification of HCV RNA. Hepatology 2000; 32: 388-393.
24. GRETCH DR, DELA ROSA C, CARITHERS RL JR. Assessment of hepatitis C viremia using molecular amplification technologies: Correlations and clinical implications. Ann Intern Med 1995; 123: 321-329.
25. MARTINOT-PEIGNOUX M, MARCELLIN P, GOURNAY J. Detection and quantitation of serum HCV-RNA by branched DNA amplification in anti-HCV positive blood donors. J Hepatol 1994; 20: 676-678.
26. HOUGHTON M, WEINER AJ, HAN J, KUO G, CHOO QL. Molecular biology of the hepatitis viruses: Implications for diagnosis, development and control of viral disease. Hepatology 1991; 14: 382-388.
27. TAKAKI A, WIESE M, MAERTENS G, DEPLA E, SEIFERT U, LIEBETRAU A. Cellular immune responses persist and humoral responses decrease two decades after recovery from a single source outbreak of hepatitis C. Nat Med 2000; 6: 578-582.
28. BURTON JR, EVERSON GT. HCV NS5B polymerase inhibitors. Clin Liver Dis 2009; 13: 453-465.